Some investors asked on the investor interactive platform: Hello, can the company’s detection products detect the mutant virus that occurred in South Africa? How is the factory operation in Ethiopia? How are the new crown products produced by the subsidiary sold in Africa?
BGI(300676.SZ) said on the investor interactive platform on November 30,BGIPay close attention to the dynamics of the new crown epidemic, and recently completed all bioinformatics analysis of Omicron. No site mutations occurred in the probe primer region of the kit, indicating that Omicron is pairedBGIThe detection performance of the new crown nucleic acid detection kit will not be affected, the detection accuracy and sensitivity will not be reduced, and it will not cause off-target and missed detection. At present, the company has formed a multi-product coverage system such as virus sequencing, nucleic acid detection, nucleic acid rapid test, antigen rapid test, antibody rapid test, neutralizing antibody test, mutant strain detection, etc., which can meet different usage needs and application scenarios.The IVD factory established by the company in Ethiopia has passedmedical instrumentsQuality management system certification (ISO 13485:2016), with local Africanmedical instrumentsProduct production capacity has laid a good foundation for the company to be based in Ethiopia and radiate to other countries in Africa, which will effectively support the company’s international strategic layout.
(Source: Daily Economic News)
Article source: Daily Economic News
Editor in charge: 108
Original title: BGI Gene: The IVD factory established by the company in Ethiopia has passed the medical device quality management system certification
Solemnly declare: The purpose of this information released by Oriental Fortune.com is to spread more information and has nothing to do with this stand.
Scan the QR code to follow
Oriental Wealth Official Website WeChat